← Back to Search

Unknown

BMS-986278 for Pulmonary Fibrosis

Phase 2
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at weeks 4, 8, 12, 16, 20, and 26
Awards & highlights

Study Summary

This trial is to study the effects of BMS-986278 on people with lung fibrosis and to see if it is safe.

Eligible Conditions
  • Pulmonary Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at weeks 4, 8, 12, 16, 20, and 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and at weeks 4, 8, 12, 16, 20, and 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of change in percent predicted forced vital capacity(ppFVC) in Idiopathic Pulmonary Fibrosis (IPF) Participants
Secondary outcome measures
Absolute change in FVC (mL) from baseline to Week 26
Absolute change in ppDLCO SB (%) (corrected for hemoglobin) from baseline to Week 26
Absolute change in ppFVC (%) from baseline to Week 26
+28 more

Trial Design

6Treatment groups
Experimental Treatment
Placebo Group
Group I: PF-ILD Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
Group II: PF-ILD Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
PF-ILD (Progressive Fibrotic Interstitial Lung Disease)
Group III: IPF Dose 2 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
Group IV: IPF Dose 1 + Post Treatment Follow-up or OTEExperimental Treatment1 Intervention
IPF (Idiopathic Pulmonary Fibrosis) OTE (Optional Treatment Extension)
Group V: PF-ILD Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention
Group VI: IPF Placebo + Post Treatment Follow-up or OTEPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
BMS-986278
2023
Completed Phase 2
~750

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,650 Previous Clinical Trials
4,130,433 Total Patients Enrolled
6 Trials studying Pulmonary Fibrosis
2,738 Patients Enrolled for Pulmonary Fibrosis
~83 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top